At close: December 13 at 4:00:01 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 1 | 4 | 3 |
| Avg. Estimate | -0.06 | 0 | -0.46 | 0.28 |
| Low Estimate | -0.22 | 0 | -0.57 | -0.41 |
| High Estimate | 0.38 | 0 | -0.17 | 1.48 |
| Year Ago EPS | -0.39 | 0.01 | 1.39 | -0.46 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 2 | 4 | 3 |
| Avg. Estimate | 7.64M | 6.36M | 10.42M | 54.67M |
| Low Estimate | -- | 1.73M | 2.77M | 17.76M |
| High Estimate | 30M | 11M | 32.77M | 116.25M |
| Year Ago Sales | 5.8M | 1.37M | 140.14M | 10.42M |
| Sales Growth (year/est) | 31.83% | 363.40% | -92.57% | 424.71% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.07 | -0.19 | -0.2 | -0.1 |
| EPS Actual | -0.39 | 0.01 | -0.3 | -0.06 |
| Difference | -0.32 | 0.2 | -0.1 | 0.04 |
| Surprise % | -437.93% | 105.15% | -48.51% | 38.46% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.06 | 0 | -0.46 | 0.28 |
| 7 Days Ago | 0 | 0 | -0.44 | 0.19 |
| 30 Days Ago | 0 | 0 | -0.44 | 0.19 |
| 60 Days Ago | 0 | 0 | -0.44 | 0.19 |
| 90 Days Ago | 0.02 | -0.16 | -0.37 | 0.11 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | 1 | -- | 2 | 2 |
| Down Last 30 Days | 1 | -- | 2 | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| SCYX | 83.33% | -100.00% | -133.27% | 161.26% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 4/1/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 8/15/2023 |
| Maintains | Guggenheim: Buy | 4/3/2023 |
| Reiterates | Ladenburg Thalmann: Buy | 4/3/2023 |
| Initiated | Guggenheim: Buy | 3/1/2023 |
| Maintains | HC Wainwright & Co.: Buy | 5/13/2022 |
Related Tickers
AKBA Akebia Therapeutics, Inc.
1.8500
+1.65%
COLL Collegium Pharmaceutical, Inc.
30.09
0.00%
AQST Aquestive Therapeutics, Inc.
3.6100
-2.17%
IRWD Ironwood Pharmaceuticals, Inc.
3.5300
-0.84%
ASRT Assertio Holdings, Inc.
0.9200
-3.32%
EGRX Eagle Pharmaceuticals, Inc.
0.7500
0.00%
ETON Eton Pharmaceuticals, Inc.
12.35
+1.56%
ELTP Elite Pharmaceuticals, Inc.
0.4900
-2.00%
AVDL Avadel Pharmaceuticals plc
10.39
-2.07%
BFRI Biofrontera Inc.
1.0600
0.00%